Clopidogrel and the risk of osteoporotic fractures: A nationwide cohort study

Journal of Internal Medicine

Volumn 272, Issue 4, 2012, Pages 385-393

  Jorgensen N R ^a   Grove, E L ^b   Schwarz, P ^a,c   Vestergaard, P ^b  

^a Mental Health Services CPH   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Bone loss; Clopidogrel; Osteoporosis; Platelet aggregation inhibitors; Spinal fracture; Thienopyridine

Indexed keywords

CLOPIDOGREL;

ACUTE CORONARY SYNDROME; AGED; ARTICLE; BONE METABOLISM; COHORT ANALYSIS; CONTROLLED STUDY; DENMARK; DRUG EFFECT; DRUG EXPOSURE; DRUG MEGADOSE; FEMALE; FOREARM FRACTURE; FRAGILITY FRACTURE; HIP FRACTURE; HUMAN; IN VIVO STUDY; INCIDENCE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK; SPINE FRACTURE; THROMBOCYTE AGGREGATION INHIBITION; TREATMENT DURATION;

AGED; COHORT STUDIES; FEMALE; HUMANS; MALE; OSTEOPOROTIC FRACTURES; PLATELET AGGREGATION INHIBITORS; RISK FACTORS; TICLOPIDINE;

EID: 84866315163     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2012.02535.x     Document Type: Article

References (22)

1. Wijns W, Kolh P, Danchin N et al. Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2010; 31: 2501-55.
2. Grove EL, Kristensen SD. Update on oral antiplatelet therapy: principles, problems and promises. Future Cardiol 2009; 5: 247-58.
3. Quinn MJ, Fitzgerald DJ. Ticlopidine and clopidogrel. Circulation 1999; 100: 1667-72.
4. Biondi-Zoccai G, Lotrionte M, Gaita F. Alternatives to clopidogrel for acute coronary syndromes: Prasugrel or ticagrelor?World J Cardiol 2010; 2: 131-4.
5. Wallentin L, Becker RC, Budaj A et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-57.
6. Wiviott SD, Braunwald E, McCabe CH et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-15.
7. Vestergaard P, Steinberg TH, Schwarz P, Jorgensen NR. Use of the oral platelet inhibitors dipyridamole and acetylsalicylic acid is associated with increased risk of fracture. Int J Cardiol 2011; Apr 2, [Epub ahead of print].
8. Ralevic V, Burnstock G. Receptors for purines and pyrimidines. Pharmacol Rev 1998; 50: 413-92.
9. Buckley KA, Golding SL, Rice JM, Dillon JP, Gallagher JA. Release and interconversion of P2 receptor agonists by human osteoblast-like cells. FASEB J 2003; 17: 1401-10.
10. Porto I, Giubilato S, De Maria GL, Biasucci LM, Crea F. Platelet P2Y12 receptor inhibition by thienopyridines: status and future. Expert Opin Investig Drugs 2009; 18: 1317-32.
11. Aster RH. Pooling of platelets in the spleen: role in the pathogenesis of "hypersplenic" thrombocytopenia. J Clin Invest 1966; 45: 645-57.
12. Vestergaard P, Emborg C, Stoving RK, Hagen C, Mosekilde L, Brixen K. Fractures in patients with anorexia nervosa, bulimia nervosa, and other eating disorders - a nationwide register study. Int J Eat Disord 2002; 32: 301-8.
13. Andersen TF, Madsen M, Jorgensen J, Mellemkjoer L, Olsen JH. The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull 1999; 46: 263-8.
14. Mosbech J, Jorgensen J, Madsen M, Rostgaard K, Thornberg K, Poulsen TD. The national patient registry. Evaluation of data quality. Ugeskr Laeger 1995; 157: 3741-5.
15. Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA III, Berger M. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 2000; 15: 721-39.
16. Kanis JA, Johansson H, Johnell O et al. Alcohol intake as a risk factor for fracture. Osteoporos Int 2005; 16: 737-42.
17. Rejnmark L, Vestergaard P, Mosekilde L. Reduced fracture risk in users of thiazide diuretics. Calcif Tissue Int 2005; 76: 167-75.
18. Rejnmark L, Vestergaard P, Mosekilde L. Treatment with beta-blockers, ACE inhibitors, and calcium-channel blockers is associated with a reduced fracture risk: a nationwide case-control study. J Hypertens 2006; 24: 581-9.
19. Rejnmark L, Vestergaard P, Mosekilde L. Fracture risk in patients treated with loop diuretics. J Intern Med 2006; 259: 117-24.
20. Munk-Jorgensen P, Mortensen PB. The Danish psychiatric central register. Dan Med Bull 1997; 44: 82-4.
21. Austin PC. The performance of different propensity-score methods for estimating relative risks. J Clin Epidemiol 2008; 61: 537-45.
22. Collet JP, Montalescot G. Optimizing long-term dual aspirin/clopidogrel therapy in acute coronary syndromes: when does the risk outweigh the benefit?Int J Cardiol 2009; 133: 8-17.